Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05873751 · ClinicalTrials.gov registry record
A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1,307,378
- Enrollment target
NCT05873751 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1,307,378 participants.
The verdict
NCT05873751 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,307,378 participants
- Enrollment target
Study Summary
Brief Summary: The main purpose of the study is to learn about how well Trumenba vaccine shot works against gonorrhea infection. This study looks at data records from a database in the United States. This study includes patient's data from the database who: * Are 15-30 years old. * Have received at least one dose of Trumenba and a MenACWY vaccine or who have received only MenACWY vaccine. This data has already been collected in the past and is being studied between April and June of 2023.
Interventions
- BIOLOGICAL Trumenba Vaccine
- BIOLOGICAL MenACWY Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,307,378 participants |
| Start Date | 2023-04-24 |
| Est. Completion | 2024-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05873751
The ClinicalTrials.gov registry entry for NCT05873751 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,307,378 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trumenba Vaccine is the first listed.
NCT05873751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05873751 about?
NCT05873751 is a clinical study titled "A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.". Brief Summary: The main purpose of the study is to learn about how well Trumenba vaccine shot works against gonorrhea infection. This study looks at data records from a database in the United States. This study includes patient's data from the database who: * Are 15-30 years old. * Have received...
What is the current status of trial NCT05873751?
This trial is currently completed. The enrollment target is 1,307,378 participants. The study started on 2023-04-24. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT05873751?
The interventions under investigation include: Trumenba Vaccine (BIOLOGICAL), MenACWY Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05873751?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.